524 related articles for article (PubMed ID: 22784966)
1. Front-line therapy in polycythemia vera and essential thrombocythemia.
Barbui T; Finazzi MC; Finazzi G
Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
[TBL] [Abstract][Full Text] [Related]
2. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
5. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
10. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
11. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
12. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
13. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Finazzi G; Barbui T
Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
15. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
16. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
17. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
18. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
19. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
Finazzi G;
Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
[TBL] [Abstract][Full Text] [Related]
20. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
Landolfi R; Marchioli R
Semin Thromb Hemost; 1997; 23(5):473-8. PubMed ID: 9387206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
